



Millendo Therapeutics Strengthens Executive Team with Key Appointments

Louis Arcudi III appointed as Chief Financial Officer

Michael Yeh appointed as Vice President of Medical Affairs

ANN ARBOR, Mich., November 14, 2018 – [Millendo Therapeutics, Inc.](#), a clinical-stage biotechnology company developing novel therapies for orphan endocrine diseases, today announced the appointments of Louis Arcudi III as Chief Financial Officer and Michael Yeh M.D., M.P.H., MBA as Vice President of Medical Affairs.

“We are delighted to welcome Lou and Michael to our management team at a pivotal time in the company’s evolution and growth,” said Julia C. Owens, Ph.D., President and Chief Executive Officer of Millendo. “These accomplished executives bring a breadth of strategic and operational skill sets that will be critical as we position our lead assets, livoletide and nevanimibe, as potential treatments for orphan endocrine diseases among the financial and medical communities.”

“I’m excited to join the team at Millendo Therapeutics, a leader in the development of orphan endocrine diseases,” said Mr. Arcudi. “I look forward to contributing to the team to help bring these important therapies to patients in need, while creating value for shareholders,” said Mr. Arcudi.

“Livoletide is a compelling late-stage therapy with the potential to address the hyperphagia that almost all patients with Prader-Willi syndrome suffer from, and what ultimately becomes the root cause of morbidity and mortality for these patients. I am excited to join the company at this time and to work with the team at Millendo to introduce transformative treatments like livoletide and nevanimibe to patients,” said Dr. Yeh.

Mr. Arcudi brings more than 20 years of financial and operational experience to Millendo. Until recently, he served as Senior Vice President of Operations and Chief Financial Officer at Idera Pharmaceuticals. Prior to Idera, he served as Vice President of Finance and Administration for Peptimmune, Inc. where he handled all financial business and operations. Before his time at Peptimmune, Mr. Arcudi served as Senior Director of Finance and Administration at Genzyme Molecular Oncology Corporation, after serving as Director of International Finance and Commercial Operations at Genzyme Corporation from 1998–2000. Earlier in his career, he held finance positions with increasing levels of responsibility at Cognex Corporation, Millipore Corporation and General Motors Corporation. Mr. Arcudi obtained an MBA from Bryant College and a B.S. in accounting and information systems from the University of Southern New Hampshire.

Dr. Michael Yeh brings more than a decade of global industry experience spanning a spectrum of therapeutic areas and encompassing a unique combination of line management, strategy consulting, medical affairs, and medical practice experience. Until recently, he served as Head of Medical Affairs for General Electric (GE) Healthcare Life Sciences Core Imaging for the United States and Canada territories. Previously, he served as Vice President and Head of Global Medical Affairs for Swedish Orphan Biovitrum (SOBI) and as Senior Medical Director and Head of the Global Medical Affairs in the multiple sclerosis franchise at Biogen. Dr. Yeh has worked in consulting roles at Tapestry Networks and Boston Consulting Group and in medical affairs at Novartis Vaccines and Diagnostics and at Genzyme Corporation. He began his career as a core faculty physician at St. Joseph Mercy Hospital, Ann Arbor. Dr. Yeh obtained an M.D. from the University of California, San Francisco, a M.S. in public health from the University of California, Berkeley, an MBA from the University of Michigan Business School and a B.S. in biology from Yale University.

About Millendo Therapeutics, Inc.

Millendo Therapeutics is focused on developing novel treatments for orphan endocrine diseases. The Company's objective is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. The Company is currently advancing livoletide for the treatment of Prader-Willi syndrome and nevanimibe for the treatment of classic congenital adrenal hyperplasia and endogenous Cushing's syndrome. For more information, please visit www.millendo.com.

###

Media Contact:

Cammy Duong
MacDougall Biomedical Communications
781-591-3443
cduong@macbiocom.com

Investor Contact:

Stephanie Ascher
Stern Investor Relations
212-362-1200
stephanie@sternir.com